Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients

Manale Doldur, Ivan Bièche, Christine Legay, Sophie Vacher, Christian Auclair, Jean Marc Ricort

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

About 70% of human breast cancers express and are dependent for growth on estrogen receptor α (ERα), and therefore are sensitive to antiestrogen therapies. However, progression to an advanced, more aggressive phenotype is associated with acquisition of resistance to antiestrogens and/or invasive potential. In this study, we highlight the role of the serine/threonine-protein kinase D1 (PKD1) in ERα-positive breast cancers. Growth of ERα-positive MCF-7 and MDA-MB-415 human breast cancer cells was assayed in adherent or anchorage-independent conditions in cells overexpressing or depleted for PKD1. PKD1 induces cell growth through both an ERα-dependent manner, by increasing ERα expression and cell sensitivity to 17β-estradiol, and an ERα-independent manner, by reducing cell dependence to estrogens and conferring partial resistance to antiestrogen ICI 182,780. PKD1 knockdown in MDA-MB-415 cells strongly reduced estrogen-dependent and independent invasion. Quantification of PKD1 mRNA levels in 38 cancerous and non-cancerous breast cell lines and in 152 ERα-positive breast tumours from patients treated with adjuvant tamoxifen showed an association between PKD1 and ERα expression in 76.3% (29/38) of the breast cell lines tested and a strong correlation between PKD1 expression and invasiveness (P <0.0001). In tamoxifen-treated patients, tumours with high PKD1 mRNA levels (n = 77, 50.66%) were significantly associated with less metastasis-free survival than tumours with low PKD1 mRNA expression (n = 75, 49.34%; P = 0.031). Moreover, PKD1 mRNA levels are strongly positively associated with EGFR and vimentin levels (P <0.0000001). Thus, our study defines PKD1 as a novel attractive prognostic factor and a potential therapeutic target in breast cancer.

Original languageEnglish
Pages (from-to)2536-2552
Number of pages17
JournalJournal of Cellular and Molecular Medicine
Volume18
Issue number12
DOIs
Publication statusPublished - 1 Dec 2014
Externally publishedYes

Fingerprint

Estrogen Receptors
Protein Kinases
Estradiol
Breast Neoplasms
Growth
Estrogen Receptor Modulators
Messenger RNA
Tamoxifen
Estrogens
Breast
Estradiol Receptors
Cell Line
Protein-Serine-Threonine Kinases
Vimentin
Neoplasms
Neoplasm Metastasis
Phenotype
Survival
Therapeutics

Keywords

  • Antiestrogen therapy
  • Breast cancer
  • Estrogen receptor α
  • Invasion
  • Proliferation
  • Protein kinase D1

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients. / Doldur, Manale; Bièche, Ivan; Legay, Christine; Vacher, Sophie; Auclair, Christian; Ricort, Jean Marc.

In: Journal of Cellular and Molecular Medicine, Vol. 18, No. 12, 01.12.2014, p. 2536-2552.

Research output: Contribution to journalArticle

Doldur, Manale ; Bièche, Ivan ; Legay, Christine ; Vacher, Sophie ; Auclair, Christian ; Ricort, Jean Marc. / Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients. In: Journal of Cellular and Molecular Medicine. 2014 ; Vol. 18, No. 12. pp. 2536-2552.
@article{7f120f0db8d54b229fb80f0c2c010784,
title = "Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients",
abstract = "About 70{\%} of human breast cancers express and are dependent for growth on estrogen receptor α (ERα), and therefore are sensitive to antiestrogen therapies. However, progression to an advanced, more aggressive phenotype is associated with acquisition of resistance to antiestrogens and/or invasive potential. In this study, we highlight the role of the serine/threonine-protein kinase D1 (PKD1) in ERα-positive breast cancers. Growth of ERα-positive MCF-7 and MDA-MB-415 human breast cancer cells was assayed in adherent or anchorage-independent conditions in cells overexpressing or depleted for PKD1. PKD1 induces cell growth through both an ERα-dependent manner, by increasing ERα expression and cell sensitivity to 17β-estradiol, and an ERα-independent manner, by reducing cell dependence to estrogens and conferring partial resistance to antiestrogen ICI 182,780. PKD1 knockdown in MDA-MB-415 cells strongly reduced estrogen-dependent and independent invasion. Quantification of PKD1 mRNA levels in 38 cancerous and non-cancerous breast cell lines and in 152 ERα-positive breast tumours from patients treated with adjuvant tamoxifen showed an association between PKD1 and ERα expression in 76.3{\%} (29/38) of the breast cell lines tested and a strong correlation between PKD1 expression and invasiveness (P <0.0001). In tamoxifen-treated patients, tumours with high PKD1 mRNA levels (n = 77, 50.66{\%}) were significantly associated with less metastasis-free survival than tumours with low PKD1 mRNA expression (n = 75, 49.34{\%}; P = 0.031). Moreover, PKD1 mRNA levels are strongly positively associated with EGFR and vimentin levels (P <0.0000001). Thus, our study defines PKD1 as a novel attractive prognostic factor and a potential therapeutic target in breast cancer.",
keywords = "Antiestrogen therapy, Breast cancer, Estrogen receptor α, Invasion, Proliferation, Protein kinase D1",
author = "Manale Doldur and Ivan Bi{\`e}che and Christine Legay and Sophie Vacher and Christian Auclair and Ricort, {Jean Marc}",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/jcmm.12322",
language = "English",
volume = "18",
pages = "2536--2552",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients

AU - Doldur, Manale

AU - Bièche, Ivan

AU - Legay, Christine

AU - Vacher, Sophie

AU - Auclair, Christian

AU - Ricort, Jean Marc

PY - 2014/12/1

Y1 - 2014/12/1

N2 - About 70% of human breast cancers express and are dependent for growth on estrogen receptor α (ERα), and therefore are sensitive to antiestrogen therapies. However, progression to an advanced, more aggressive phenotype is associated with acquisition of resistance to antiestrogens and/or invasive potential. In this study, we highlight the role of the serine/threonine-protein kinase D1 (PKD1) in ERα-positive breast cancers. Growth of ERα-positive MCF-7 and MDA-MB-415 human breast cancer cells was assayed in adherent or anchorage-independent conditions in cells overexpressing or depleted for PKD1. PKD1 induces cell growth through both an ERα-dependent manner, by increasing ERα expression and cell sensitivity to 17β-estradiol, and an ERα-independent manner, by reducing cell dependence to estrogens and conferring partial resistance to antiestrogen ICI 182,780. PKD1 knockdown in MDA-MB-415 cells strongly reduced estrogen-dependent and independent invasion. Quantification of PKD1 mRNA levels in 38 cancerous and non-cancerous breast cell lines and in 152 ERα-positive breast tumours from patients treated with adjuvant tamoxifen showed an association between PKD1 and ERα expression in 76.3% (29/38) of the breast cell lines tested and a strong correlation between PKD1 expression and invasiveness (P <0.0001). In tamoxifen-treated patients, tumours with high PKD1 mRNA levels (n = 77, 50.66%) were significantly associated with less metastasis-free survival than tumours with low PKD1 mRNA expression (n = 75, 49.34%; P = 0.031). Moreover, PKD1 mRNA levels are strongly positively associated with EGFR and vimentin levels (P <0.0000001). Thus, our study defines PKD1 as a novel attractive prognostic factor and a potential therapeutic target in breast cancer.

AB - About 70% of human breast cancers express and are dependent for growth on estrogen receptor α (ERα), and therefore are sensitive to antiestrogen therapies. However, progression to an advanced, more aggressive phenotype is associated with acquisition of resistance to antiestrogens and/or invasive potential. In this study, we highlight the role of the serine/threonine-protein kinase D1 (PKD1) in ERα-positive breast cancers. Growth of ERα-positive MCF-7 and MDA-MB-415 human breast cancer cells was assayed in adherent or anchorage-independent conditions in cells overexpressing or depleted for PKD1. PKD1 induces cell growth through both an ERα-dependent manner, by increasing ERα expression and cell sensitivity to 17β-estradiol, and an ERα-independent manner, by reducing cell dependence to estrogens and conferring partial resistance to antiestrogen ICI 182,780. PKD1 knockdown in MDA-MB-415 cells strongly reduced estrogen-dependent and independent invasion. Quantification of PKD1 mRNA levels in 38 cancerous and non-cancerous breast cell lines and in 152 ERα-positive breast tumours from patients treated with adjuvant tamoxifen showed an association between PKD1 and ERα expression in 76.3% (29/38) of the breast cell lines tested and a strong correlation between PKD1 expression and invasiveness (P <0.0001). In tamoxifen-treated patients, tumours with high PKD1 mRNA levels (n = 77, 50.66%) were significantly associated with less metastasis-free survival than tumours with low PKD1 mRNA expression (n = 75, 49.34%; P = 0.031). Moreover, PKD1 mRNA levels are strongly positively associated with EGFR and vimentin levels (P <0.0000001). Thus, our study defines PKD1 as a novel attractive prognostic factor and a potential therapeutic target in breast cancer.

KW - Antiestrogen therapy

KW - Breast cancer

KW - Estrogen receptor α

KW - Invasion

KW - Proliferation

KW - Protein kinase D1

UR - http://www.scopus.com/inward/record.url?scp=84911435381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911435381&partnerID=8YFLogxK

U2 - 10.1111/jcmm.12322

DO - 10.1111/jcmm.12322

M3 - Article

C2 - 25287328

AN - SCOPUS:84911435381

VL - 18

SP - 2536

EP - 2552

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 12

ER -